X

Trial Profile

A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer.

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasatinib (Primary) ; Gemcitabine (Primary)
Indications Pancreatic cancer; Solid tumours
Focus Adverse reactions; Biomarker

Most Recent Events

22 Jun 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
22 Jun 2012 Actual patient number 30 added as reported by ClinicalTrials.gov.
22 Jun 2012 Planned End Date changed from 1 Jun 2011 to 1 May 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com